GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Current Ratio

Nicox (FRA:NXOA) Current Ratio : 1.46 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Nicox Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Nicox's current ratio for the quarter that ended in Jun. 2024 was 1.46.

Nicox has a current ratio of 1.46. It generally indicates good short-term financial strength.

The historical rank and industry rank for Nicox's Current Ratio or its related term are showing as below:

FRA:NXOA' s Current Ratio Range Over the Past 10 Years
Min: 1.26   Med: 3.34   Max: 9.28
Current: 1.46

During the past 13 years, Nicox's highest Current Ratio was 9.28. The lowest was 1.26. And the median was 3.34.

FRA:NXOA's Current Ratio is ranked worse than
76.02% of 1497 companies
in the Biotechnology industry
Industry Median: 3.65 vs FRA:NXOA: 1.46

Nicox Current Ratio Historical Data

The historical data trend for Nicox's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Current Ratio Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.27 3.41 5.97 9.28 8.97

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 9.28 2.57 8.97 1.46

Competitive Comparison of Nicox's Current Ratio

For the Biotechnology subindustry, Nicox's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Current Ratio distribution charts can be found below:

* The bar in red indicates where Nicox's Current Ratio falls into.


;
;

Nicox Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Nicox's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=51.123/5.701
=8.97

Nicox's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=13.529/9.284
=1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox  (FRA:NXOA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Nicox Current Ratio Related Terms

Thank you for viewing the detailed overview of Nicox's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox Business Description

Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines